Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · Real-Time Price · USD
1.400
+0.100 (7.69%)
At close: Dec 20, 2024, 4:00 PM
1.420
+0.020 (1.42%)
After-hours: Dec 20, 2024, 6:35 PM EST
7.69%
Market Cap 80.40M
Revenue (ttm) n/a
Net Income (ttm) -28.17M
Shares Out 57.43M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 449,460
Open 1.310
Previous Close 1.300
Day's Range 1.300 - 1.415
52-Week Range 1.300 - 8.750
Beta 0.05
Analysts Strong Buy
Price Target 11.80 (+742.86%)
Earnings Date Nov 14, 2024

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibod... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol RANI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price forecast is $11.8, which is an increase of 742.86% from the latest price.

Price Target
$11.8
(742.86% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

2 months ago - GlobeNewsWire

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...

2 months ago - GlobeNewsWire

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...

3 months ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -

4 months ago - GlobeNewsWire

Rani Therapeutics to Participate in August Investor Conferences

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

5 months ago - GlobeNewsWire

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

5 months ago - GlobeNewsWire

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism wi...

6 months ago - GlobeNewsWire

Rani Therapeutics to Participate in May Investor Conferences

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...

7 months ago - GlobeNewsWire

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...

8 months ago - GlobeNewsWire

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expect...

8 months ago - GlobeNewsWire

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Tr...

9 months ago - GlobeNewsWire

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...

10 months ago - GlobeNewsWire

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –

1 year ago - GlobeNewsWire

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, ...

1 year ago - GlobeNewsWire

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -

1 year ago - GlobeNewsWire

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

1 year ago - GlobeNewsWire

Rani Therapeutics: Excellent Technology But Major Risks Ahead

RANI is developing a payload agnostic robotic pill (RaniPill) with enormous potential for penetration of several multi-billion injectable drug delivery markets. Pre-clinical and early-phase human stud...

1 year ago - Seeking Alpha

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSW...

1 year ago - GlobeNewsWire

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate

1 year ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstr...

1 year ago - GlobeNewsWire

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

1 year ago - GlobeNewsWire

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

1 year ago - GlobeNewsWire

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111 This is the second deal announced between Rani and ...

1 year ago - GlobeNewsWire

Rani Therapeutics to Present at the Jefferies Healthcare Conference

SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

1 year ago - GlobeNewsWire